CD276 and neoplasm: Combination with Nanobody: Researchers have developed a single-domain camel nanoantibody B7H3nb with high affinity for B7H3, a tumor-associated antigen that is overexpressed in various cancers and underexpressed in normal tissues [54,55], and combined it with a single-chain variable fragment (scFv) targeting CD3 to create a bispecific antibody, B7H3nb/CD3, which significantly enhanced cytotoxic activity by redirecting T cells to B7H3-expressing tumor cells.